Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader […]
AMMO, Inc. Reports Fourth Quarter and Fiscal Year 2024 Financial Results
SCOTTSDALE, Ariz., June 13, 2024 (GLOBE NEWSWIRE) — AMMO, Inc. (Nasdaq: POWW, POWWP) (“AMMO” or the “Company”), the owner of […]
Beyond Air® Appoints David Webster as Chief Commercial Officer
GARDEN CITY, N.Y., June 13, 2024 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a […]
iLearningEngines Partners with ULTS to Revolutionize Corporate Training with Learning Automation Platform
BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) — iLearningEngines, Inc. (Nasdaq: AILE) (“iLearningEngines” or “the Company”), a leader in AI-powered […]
QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs
Venlo, the Netherlands, and Redwood City, California, June 13, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) […]
Howard Hughes Holdings Inc. Closes on Refinancing of 9950 Woodloch Forest Drive in the Woodlands®
THE WOODLANDS, Texas, June 13, 2024 (GLOBE NEWSWIRE) — Howard Hughes Holdings Inc. (NYSE: HHH) announced today the closing on […]
WillScot Mobile Mini Holdings Announces Pricing of $500 Million Senior Secured Notes Offering
PHOENIX, June 13, 2024 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), […]
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic […]
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia […]
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed […]
